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ABSTRACT
Shortening of telomeres along with an up-regulation
of telomerase is implicated in the immortality of tumor
cells. Targeting either telomeres or telomerase with spe-
cific compounds has been proposed as an anticancer strat-
egy. Because telomerase activity and telomeres are found
in normal cells, telomere or telomerase targeting agents
could induce side effects in normal tissues. We evaluated
the effects of telomere and telomerase interactive agents
in human tumor and normal cell lines to try to determine
the potential side effects those agents might induce in
patients. Toxicity of the G-quadruplex interactive por-
phyrins (TMPyP4, TMPyP2) and azidothymidine (AZT)
were tested using a cell-counting technique against nor-
mal human cell lines (CRL-2115 and CRL-2120, fibro-
blasts; NHEK-Ad, adult keratinocytes; CCL-241, small
intestinal cells; NCM 460, colonic mucosal epithelial cells)
and human tumor cell lines (MDA-MB 231 and Hs 578T,
breast cancer; SK-N-FI, neuroblastoma; HeLa, cervix
cancer; MIA PaCa-2, pancreatic cancer; HT-29 and
HCT-116, colon cancer; DU 145, prostatic cancer cell
line). Telomerase activity of these cell lines was measured
by a non-PCR-based conventional assay. The effects of
TMPyP2, TMPyP4, and AZT were also evaluated against
normal human bone marrow specimens, using a granulo-
cyte-macrophage colony-forming assay (CFU-GM). AZT
showed very low cytotoxic effects against normal and
tumor cell lines, with the IC50 values above 200 mM. The
IC50 values for TMPyP2 and TMPyP4 in normal human
cell lines were in the range of 2.9 – 48.3 mM and 1.7–15.5
mM, respectively, whereas in tumor cell lines the IC50
values were 11.4 –53 mM and 9.0 –28.2 mM, respectively.
Within the tissue types, keratinocytes were more sensitive
to TMPyP4 than fibroblasts, and small intestinal cells
were more sensitive than colonic mucosal epithelial cells.
The IC50 for TMPyP2 and TMPyP4 in the normal mar-
row colony-forming assays were 19.3 6 5.1 mM and 47.9 6
1.0 mM, respectively. In conclusion, the in vitro cytotoxic-
ity of the telomere interactive agent TMPyP4 is compa-
rable in human tumor and normal cell lines, which indi-
cates that TMPyP4 could have effects on normal tissues.
INTRODUCTION
Cellular senescence, defined by the limited proliferative
capacity of normal cells, enables maintenance of homeostasis of
the human body. Although some cells become transformed
through various processes (1), transformed cells eventually un-
dergo a proliferative crisis followed by cell death. Tumor cells
must overcome this regulatory mechanism and immortalize to
proliferate indefinitely. One of the most important processes of
immortalization is the reactivation of telomerase activity to
maintain the telomere length (2–4).
Shortening of telomeres along with an up-regulation in
telomerase is implicated in the immortality of tumor cells
(3–5). Targeting either telomeres or telomerase with specific
compounds has been proposed as an anticancer strategy with
tumor specificity (6 –9). Recent understanding of the spatial
structure of telomeric DNA, folded into G-quartet structures,
led to the design of compounds interacting more specifically
with the telomeric G-quartet, which may influence the extent
of telomere elongation and finally induce the death of tumor
cells (9, 10). On the basis of this information, the porphyrin
TMPyP4 was developed as a candidate telomere interactive
agent that interacts with the G-quartet specifically by an
external stacking interaction. Meanwhile, the porphyrin
TMPyP2, an isomer of TMPyP4, has demonstrated a different
interaction with the G-quadruplex from TMPyP4 because it is
sterically hindered from an external stacking (11). In addi-
tion, TMPyP4 has a telomerase-inhibitory effect in a cell-free
system and in intact cancer cells (10, 12). TMPyP4 is a
promising agent targeting both telomere and telomerase.
Telomerase is composed of a template RNA and catalytic
subunit, hTERT, which has been shown to be closely related to
other reverse transcriptases (13, 14). To achieve more specific
targeting of telomerase, there have been many in vitro and in
vivo trials using peptide nucleic acids, oligonucleotides as an
Received 8/11/99; revised 11/16/99; accepted 11/22/99.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
1 Supported by an American Cancer Society International Fellowship
for Beginning Investigator of International Union Against Cancer
(UICC) Award and a National Cooperative Drug Discovery Group grant
(CA67760) from the National Cancer Institute, Department of Health
and Human Services.
2 To whom requests for reprints should be addressed, at 7979 Wurzbach
Road, Room 337, San Antonio, TX 78229. Phone: (210) 616-5892; Fax:
(210) 616-5948; E-mail: srha@saci.org.
987Vol. 6, 987–993, March 2000 Clinical Cancer Research
Research. 
on October 29, 2018. © 2000 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
antisense, or using AZT3 as an inhibitor of reverse transcriptase
(15–17). In our previous reports, we showed that these telomere
and telomerase interactive agents affected the proliferation rates
and induced chromosomal instability not only in in vitro cell
lines but also in a sea urchin embryo in vivo system, which is an
effective model to evaluate the biological effects of novel agents
(18).
To date, telomerase activity has been detected in some
normal cells, including peripheral blood, cord blood and bone
marrow lymphocytes, the basal layer of the skin, crypt cells of
the proliferating intestinal epithelium, endometrium, proliferat-
ing endothelium, and in some benign breast epithelium (19–27).
Although the telomerase activity in those tissues is lower than in
most tumors and because all cells have telomeres, the telomere
and telomerase targeting agents could induce side effects in
these normal tissues. Conceivably, a combination of chemother-
apeutic agents with these telomere and telomerase interactive
agents could exaggerate the side effects in proliferating normal
tissues. For the present study, we have evaluated the effects of
telomere and telomerase interactive agents against human tumor
and normal cell lines to try to predict the side effects those
agents may induce in patients.
MATERIALS AND METHODS
Cell Lines. All of the human tumor cell lines (MDA-MB
231 and Hs 578T, breast cancer; SK-N-FI, neuroblastoma;
HeLa, cervix cancer; MIA PaCa-2, pancreatic cancer; HT-29
and HCT-116, colon cancer; and DU 145, prostatic cancer cell
line), two normal human skin fibroblasts (CRL-2115 and CRL-
2120) and one normal intestinal cell line (CCL-241) were ob-
tained from American Type Culture Collection (Rockville,
MD). An adult normal human keratinocyte cell line (NHEK-Ad)
was obtained from Clonetics Corporation (San Diego, CA). The
normal human colonic epithelium cell line (NCM 460; Ref. 28)
was purchased from INCELL Corporation (San Antonio, TX).
All of the cell lines were grown according to the supplier’s
instructions. The characteristics of the cell lines that were used
for the study are summarized in Table 1.
Telomere and Telomerase Interactive Agents. The G-
quadruplex interactive tetracationic porphyrin (TMPyP4) and
the positional isomer, TMPyP2 (used as a control of interest),
were obtained from Midcentury (Posen, IL). All of the experi-
ments with porphyrins were performed under minimum expo-
sure to light except for the photoactivation experiment. The
reverse transcriptase inhibitor, AZT, was purchased from Sigma
Chemical Co (St. Louis, MO).
Determination of Telomerase Activity. Telomerase ac-
tivity of normal human cell lines was measured using a non-
PCR-based, conventional telomerase assay with 59-biotinylated
d(TTAGGG) as a telomere primer (29). Briefly, cell extracts
were obtained from 1 3 107 cell pellets after washing with PBS.
The cell pellet was washed once with ice-cold washing buffer
[10 mM HEPES-KOH (pH 7.5), 1.5 mM MgCl2, 10 mM KCl, and
1 M DTT] and then pelleted again at 10,000 3 g for 1 min at
4°C. The pellet was resuspended in 100–400 ml of ice-cold lysis
buffer containing 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM
EGTA, 0.1 mM phenyl-methylsulfonyl fluoride, 5 mM b-mer-
captoethanol, 1 mM DTT, 0.5% 3-[(3-cholamidopropyl) di-
methylammonio]-1-propane sulfonate, 10% glycerol and 40
UI/ml RNase guard. After incubation on ice for 30 min, the
lysates were transferred to polyallomer tubes (Beckman, Fuller-
ton, CA) and spun at 100,000 3 g for 1 h at 4°C in a tabletop
ultracentrifuge. The supernatants were stored at 280°C in 10%
glycerol. Protein concentrations were determined by the Brad-
ford assay (Bio-Rad, Hercules, CA). All of the cell line extracts
were normalized to the same protein concentration of 1 mg/ml.
For the telomerase reaction, the reaction mixture (20 ml)
containing 4 ml of cell lysate, 50 mM Tris acetate (pH 8.5), 50
mM potassium acetate, 1 mM MgCl2, 5 mM b-mercaptoethanol,
1 mM spermidine, 1 mM telomere primer, 1.5 M [a-32P]dGTP
(800 Ci/mmol), 2 mM dATP, and 2 mM dTTP were incubated at
37°C for 1 h. The reactions were terminated by adding 20 ml of
streptavidin-coated Dynabead suspension containing 10 mM
Tris-HCl (pH 7.5) and 2 M NaCl. The beads complexed selec-
tively with the 59-biotinylated DNA. The complex was sepa-
rated from the suspension using a magnet (Dynal MPC) and
washed several times with washing buffer (1 M NaCl) to elim-
inate [a-32P]dGTP background. Telomerase reaction products
were separated from the magnetic beads by protein denaturation
with 5.0 M guanidine hydrochloride at 90°C for 20 min. After
ethanol precipitation, the reaction products were analyzed by
8% PAGE. Telomerase activity in HeLa cell extracts were used
for reference and defined as 100% activity.
Cytotoxicity Assay. A cell proliferation assay was per-
formed by a cell-counting technique using Coulter ZM counter
(Coulter Electronics, Luton, United Kingdom). Exponentially
growing 5 3 103 cells in 1 ml of medium were plated in 24-well
microtiter plates on day 0. On day 1, 1 ml of fresh medium
containing various concentrations of the drugs was added to the
plate. On days 4 and 7, the cells were trypsinized, and the cells
were counted with the Coulter counter. Each assay was per-
formed in duplicate. The IC50 for the drug was determined by
the EZ50 software program (Perrella Scientific Inc., Amherst,
NH).
3 The abbreviations used are: AZT, azidothymidine; CFU-GM, granu-
locyte-macrophage colony-forming unit(s).
Table 1 Characteristics of the cell lines
Name Origin Source Passages
Normal human cell lines
CCL-241 Intestinal epithelium ATCC 27–30
NCM-460 Colonic epithelium INCELL Co. 38–40
CRL-2115 Skin fibroblast ATCC 7–9
CRL-2120 Skin fibroblast ATCC 7–9
NHEK-Ad Adult keratinocyte Clonetics Co. 3–4
Human tumor cell lines
MDA-MB-231 Breast cancer ATCC
HS578T Breast cancer ATCC
SK-N-FI Neuroblastoma ATCC
HeLa Cervix cancer ATCC
MIA-Paca-2 Pancreatic cancer ATCC
HT-29 Colon cancer ATCC
HCT-116 Colon cancer ATCC
DU 145 Prostatic cancer ATCC
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Photoactivation Effects on the Cytotoxicity of Porphy-
rins. Because porphyrins are known photosensitizers and can
cause nonspecific DNA damage on light exposure, we evaluated
the effects of photoactivation of TMPyP2 and TMPyP4 on
normal cells. The cells were cultured in 24-well plates in the
continuous presence of the various concentrations of com-
pounds under limited light exposure (“dark”), which is a stand-
ard way of handling the porphyrins in all of the bioassays in our
laboratories. Photoactivation of cells treated with porphyrins in
separate plates was achieved by a daily 15-min exposure for 5
days to a 60-W light source 12 inches above the flasks (“light”).
This light treatment was not associated with any thermal effects
on the cells. The IC50 values were determined by cell counts in
both sets of plates.
CFU-GM Assay. The cytotoxic effects of telomere and
telomerase interactive agents on normal human bone marrow
colony-forming units were assessed by examining the number of
CFU-GM-derived colonies. Briefly, bone marrow mononuclear
cells were collected from normal healthy bone marrow donors
after informed consent as described previously (30). These
studies were approved by the Institutional Review Board of the
University of Texas Health Science Center at San Antonio.
Nonadherent bone marrow cells were recovered after 2-h incu-
bation in plastic tissue culture dishes and plated in 35-mm tissue
culture dishes at 105 cells/ml in a 1-ml volume of 1.5% meth-
ylcellulose (Aldrich Chemical Co., Milwaukee, MI) supple-
mented with 20% heat-inactivated FCS (Tissue Culture Biologi-
cals, Tulare, CA), BSA (Sigma Chemical Co.), 1.0 ng/ml
recombinant human granulocyte macrophage colony-stimulat-
ing factor and different concentrations of the drugs. Each assay
was performed in triplicate. The number of the colonies was
counted after 14 days incubation in 5% CO2 at 37°C.
RESULTS
Selection of the Telomere and Telomerase Interactive
Agents and Cell Lines. Recent understanding of the spatial
structure of telomeric DNA, folded into G-quartet structures, led
to the design of compounds interacting more specifically with
telomeric G quartets, which may influence the extent of te-
lomere elongation and finally induce the death of tumor cells
(9–11). Among many candidate compounds, the cationic por-
phyrin, TMPyP4 [5,10,15,20-tetra(N-methyl-4-pyridyl) por-
phinchloride], was found to effectively stack with the G tetrads
to stabilize quadruplex DNA. In addition, TMPyP4 has the
significant telomerase inhibitory effects not only in a HeLa
cell-free system but also in intact breast cancer cells in a dose-
and time-dependent manner (12). In the present study, we have
chosen TMPyP4 as a specific G-quadruplex interactive agent.
As a control agent of interest, we used TMPyP2, the isomer of
TMPyP4 that has a less specific interaction with G-quadru-
plexes. Recent reports provide evidence that the catalytic sub-
unit of telomerase (hTERT) is more important for the capacity
of telomerase to confer immortalization on tumor cells than the
RNA subunit of telomerase (13, 14). The hTERT subunit of
telomerase is very similar to reverse transcriptase; therefore,
AZT has been selected as a telomerase-specific inhibitor that
works through inhibition of reverse transcriptase.
The porphyrins are already used clinically in dermatology
and oncology (31), and some interaction between porphyrins
and normal skin cells might be expected. Telomerase activity is
detected not only in the basal cell of the skin but also in the
keratinocyte (21). Therefore, we selected normal human skin
fibroblasts and adult human keratinocytes as target cell lines.
Intestinal epithelium is a rapidly proliferating tissue that is often
susceptible to chemotherapy and is known to have telomerase
activity. We also selected a normal human intestinal cell line
and a normal colonic mucosal epithelial cell line for prediction
of possible side effects on those rapidly proliferating cells. To
evaluate the effect of telomere and telomerase interactive
agents on hematopoietic cells more precisely, we studied
normal human bone marrow cells using a colony forming
assay. As positive controls, we used eight human tumor cell
lines with known various telomerase activities and telomere
lengths (Table 1).
Determination of Telomerase Activity. All of the tumor
cell lines that were used for this study showed telomerase
activity. Telomerase activity levels for the normal human cell
lines, found by using the non-PCR based conventional telom-
erase assay are shown in Fig. 1. All of the normal human cell
lines showed relatively weak telomerase activity compared with
Fig. 1 Telomerase activity of normal human cell lines as assayed by a
non-PCR-based conventional assay. A, Lane 1, HeLa cell extract; Lane
2, NCM 460 (colonic mucosal epithelium) cells. B, Lane 1, HeLa cell
extract; Lane 2, HeLa extract with RNase treatment; Lane 3, CRL-2115
(skin fibroblast) cell line; Lane 4, CRL-2115 with RNase treatment;
Lane 5, CRL-2120 (skin fibroblast) cell line; Lane 6, CRL-2120 with
RNase treatment; Lane 7, Ad-NHEK (adult keratinocyte) cell line; Lane
8, Ad-NHEK with RNase treatment.
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the activity of HeLa cell extracts used as a reference. Among
them, only one colonic mucosal epithelial cell line showed weak
processive telomerase activity in this conventional assay. The
other four cell lines showed nonprocessive telomerase activity.
Telomerase activity in skin fibroblast (CRL-2115) cells was
relatively strong (Fig. 1).
Photoactivation Effects on the Cytotoxicity of Porphy-
rins. We tested the photoactivation effects on two different
normal fibroblast cells. The IC50 values for TMPyP2 and
TMPyP4 under the dark condition described above were 28.1
mM and 7.3 mM in CRL-2115 cells and 22.6 mM and 15.5 mM in
CRL-2120 cells. With these dark conditions, TMPyP4 was more
cytotoxic than TMPyP2. After the treatment with light for 5
days as described above, the IC50 values for TMPyP2 and
TMPyP4 were decreased to 2.25 mM and 1.5 mM, respectively, in
CRL-2115 cells and 11.8 mM and 11.6 mM, respectively in
CRL–2120 cells. When we treated the CRL-2115 fibroblast
cells with 5 mM and 10 mM of TMPyP2 and TMPyP4, TMPyP2
did not substantially affect the cell growth with limited light.
However, when exposed to light, TMPyP2 induced the same
cytotoxic effect as TMPyP4 did. Because the light induced the
same cytotoxicity with TMPyP2 and TMPyP4, it suggested to us
that there is a nonspecific effect of these agents related to the
light (Fig. 2).
Cytotoxicity Assay. The cell proliferation assay results
for the eight tumor cell lines and five normal cell lines were
compared based on the cell-counting technique. Because of the
light sensitivity of porphyrins, we handled the cell plates under
the limited light conditions described above. The IC50 values for
TMPyP2 and TMPyP4 in tumor cell lines were in the range of
11.4–53 mM and 9.0–28.2 mM, respectively, whereas AZT
showed very low cytotoxic effects against tumor cell lines
(Table 2). There was no apparent correlation between cytotox-
icity and the tumor types or telomerase activities of the tumor
cell lines. The IC50 values for TMPyP2 and TMPyP4 in normal
human cell lines were in the range of 2.9–48.3 mM and 1.7–15.5
mM, respectively, whereas AZT showed very low cytotoxic
effects just as in tumor cell lines (Table 3). Within the tissue
types, keratinocytes were more sensitive to TMPyP4 than fibro-
blasts, and the small intestine-derived cells were more sensitive
than colonic mucosal epithelial cells. TMPyP4 was more cyto-
toxic than TMPyP2 in tumor and normal cells.
CFU-GM Assay. The cytotoxic effects of TMPyP4 on
hematopoietic cells from 10 healthy normal human bone mar-
row donors were assessed by examining the number of CFU-
GM. The IC50 for TMPyP4 in the normal marrow colony-
forming assays was 47.9 mM (Fig. 3A). The effects of TMPyP2
and AZT were evaluated with four normal human bone marrow
Fig. 2 The light effects in growth inhibition of the porphyrins in normal fibroblast cell line (CRL-2115). The cell numbers were counted by Coulter
counter after the cells were grown in 24-well plates with the various concentrations of the TMPyP2 and TMPyP4 after incubation under the light for
15 min 5 days a week.
Table 2 Mean IC50 for inhibition of cell growth by telomere and telomerase interactive agents on tumor cell lines using cell-counting technique
Cell line Tumor type
Relative telomerase
activitya
IC50 (mM)
TMPyP2 TMPyP4 AZT
MDA-MB-231 Breast cancer 111 53.0 25.0 .200
HS578T Breast cancer 1 11.4 9.0 .200
SK-N-FI Neuroblastoma 11 16.3 42.0 .200
HeLa Cervix cancer 11 22.8 18.5 .200
MIA-Paca-2 Pancreatic cancer 11 32.4 21.9 .200
HT-29 Colon cancer 1 31.8 11.0 .200
HCT-116 Colon cancer 1 37.4 28.2 .200
DU 145 Prostatic cancer 6 26.5 21.6 .200
a Relative telomerase activity compared with the activity of HeLA cell extract level of 11.
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cells, and the IC50 values were 19.3 mM and 86.9 mM, respec-
tively (Fig. 3, B and C).
DISCUSSION
It is increasingly apparent that telomerase activity is pres-
ent in many normal cells including hematopoietic cells, kerati-
nocytes, crypt cells of intestinal epithelium, and others (19–27).
Although the telomerase activity in those normal tissues is
weaker than tumor tissues, and its relevance is yet to be clari-
fied, telomerase-targeting agents could induce side effects in
those normal tissues. Also, telomeres in normal cells may be
affected by telomere interactive agents. In preparation for the
introduction of a telomere and telomerase interactive agent into
clinical trials, we evaluated the possible effects of such agents
on human tumor and normal cell lines to try to predict the side
effects those compounds may induce in cancer patients.
As baseline information, all of the five normal human cell
lines showed weak telomerase activity. This is not surprising
because, although these cell lines are known as normal in
character with a limited life span, they are growing in culture
under stable conditions. Interestingly, only one cell line (a
colonic mucosal epithelial cell line) showed a weak processive
telomerase activity. Possible explanations for this processive
telomerase activity in colonic epithelial cells are: (a) this cell
line has properties of stem cells of the colonic epithelium; and
(b) this cell line has been selected for continuous in vitro culture
(it was tested at 38th passage), which means that it could
possibly be in the process of immortalization but maintains a
colon cell phenotype.
Porphyrins are photosensitizing agents that are effectively
used in diagnosis and therapy in dermatology and oncology
(31). Keratinocytes and skin cells are the normal tissues express-
ing telomerase activity, and those cells may be more affected by
porphyrins because of photosensitivity. On the basis of this
assumption, we evaluated the photoactivation effects on the
cytotoxicity of porphyrins on normal cell lines. Indeed,
TMPyP2 and TMPyP4 showed more toxic effects under light
exposure. After the light treatment, the cytotoxicity of TMPyP2
was similar to that of TMPyP4, which suggested that the non-
specific cytotoxicity of these drugs could be related to the light.
Therefore, one must pay attention to possible photosensitivity
side effects from telomere and telomerase interactive porphyrin
treatment, especially in the sun-exposed skin.
Using the cell-counting techniques, we observed similar
toxicity of the agents tested in normal cell lines compared with
tumor cell lines. We also observed that TMPyP2 was less
cytotoxic in normal and tumor cell lines in comparison with
TMPyP4. The cytotoxic effect of telomere and telomerase in-
teractive agents against normal human marrow cells in the
colony-forming assay showed the same range of IC50 as in other
normal cell lines.
There was no difference in cytotoxicity according to the
tumor types or telomerase activities of the tumor cell lines,
consistent with our previous results (12). Because the main
mechanism of action of TMPyP4 is via interaction with telo-
meric DNA, it is not surprising that there is not a correlation
between the cytotoxic effect of TMPyP4 and the levels of
telomerase activity. Furthermore, the lack of cytotoxicity with
AZT, which inhibits telomerase activity, is not surprising, given
that the direct inhibition of telomerase activity is not enough to
induce cell growth inhibition in a short period of time. Compa-
rable toxicity of porphyrins in tumor and normal cells supports
the hypothesis that these compounds target telomeres rather than
telomerase.
Because all of the cells have telomeres, tumor selectivity of
these telomere and telomerase interactive agents is the main
problem to solve. Possible ways to enhance tumor selectivity by
these agents include: (a) tumor cells may have different types of
the G-quadruplexes, which could be the specific target of
TMPyP4; (b) because the maintenance of telomeres is known to
be regulated by the telosome, the complex of telomere, telom-
erase, and the regulatory proteins of telomerase or telomeres
[such as TRF1,2; hnRNP A1; or TP (telomerase binding pro-
tein); Refs. 32–34], there may be a unique role of telomere- and
telomerase-related proteins to form G-quadruplexes with telo-
meric DNA in tumor cells, which may give some selectivity; (c)
porphyrins are known to be rapidly and preferentially taken up
by the tumor cells (35, 36); and (d) rapidly proliferating cells,
such as some tumor cells, may give more opportunity for the
porphyrins to interact with G quadruplexes formed by single-
strand overhangs.
Up to now, telomere and telomerase interactive agents
have been regarded as probable cytostatic agents that could
be more effective in combination with common chemother-
apeutic agents. Some limitations of chemotherapy are side
effects on proliferating normal somatic cells, such as bone
marrow and mucosal cells. The results from our study indi-
cate that the spectrum of side effects of telomere and telom-
erase interactive agents and chemotherapeutic agents might
overlap. Certainly, combining telomere and telomerase inter-
active agents with chemotherapeutic agents will have to be
done with caution.
There are some difficulties inherent in using in vitro nor-
mal cell systems to evaluate the cytotoxicities of telomere and
telomerase interactive agents: (a) normal cells are fragile in in
vitro culture systems. Thus, the normal cell lines that we used
could be more susceptible to the agents tested because of this
fragility; (b) normal cells have a limited life span. Because of
that finite life span, we could not evaluate the effect of long term
culture. This study provides us only with a spectrum of short-
term toxicity against normal cell lines; (c) normal cells are in the
process of senescence. The cytotoxic effect of telomere and
Table 3 Mean IC50 for inhibition of cell growth by telomere and
telomerase interactive agents on normal human cell lines using cell-
counting technique
Cell line (tissue type)
IC50 (mM)
TMPyP2 TMPyP4 AZT
CRL-2115 (fibroblast)a 28.1 7.3 .200
CRL-2120 (fibroblast)a 22.6 15.5 .200
NHEK-Ad (keratinocyte)b 2.9 1.7 .200
CCL-241 (intestine)b 48.3 5.3 .200
NCM-460 (colon)b 11.1 7.5 .200
a Mesenchymal cells.
b Epithelial cells.
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telomerase interactive agents in the normal cell lines could be
exaggerated in the process of senescence.
Despite the above obstacles, our data indicate that the
porphyrin class of telomere and telomerase interactive agents
may affect normal cells. To enhance the target specific effects,
additional studies to exploit the mechanism of action of these
agents are warranted. A substantial program is under way to
develop nonphotosensitive porphyrin analogues to reduce the
potent side effects and to enhance the tumor specificity of these
agents.
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